TREAT YOUR ELIGIBLE PATIENTS WITH FLEXIBILITY
Extend up to 6-month intervals* and experience flexibility with optional reloading for patients switching from other anti-VEGF agents†
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
Key steps for administering EYLEA 8 mg
Using aseptic technique, attach the filter needle supplied in the carton to a 1 mL sterile Luer Lock syringe.
Disclaimer: These instructions are not complete. For full instructions, please download the instructions for use (IFU) card above and refer to the EYLEA 114.3 mg/mL Summary of Product Characteristics.
*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.
†Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. Consult the SmPC for full posology.
Watch the EYLEA 8 mg injection training video
Prescribing information for EYLEA® (aflibercept) can be found here.
Abbreviations
DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q16, every 16 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.
PP-EYL-GB-2899 | September 2025